Literature DB >> 29248585

Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human.

Seiya Yamayoshi1, Mutsumi Ito1, Ryuta Uraki1, Tadahiro Sasaki2, Kazuyoshi Ikuta2, Yoshihiro Kawaoka3.   

Abstract

OBJECTIVES: Broadly reactive human monoclonal antibodies against the HA stem of influenza A virus are being developed as therapeutic agents as well as to understand the epitopes that are essential for a universal influenza virus vaccine.
METHODS: We isolated and characterized two hetero-reactive human monoclonal antibodies from an H3N2 virus-infected human.
RESULTS: These antibodies, which are predominantly bound to the HA stem of group 2 HAs, used IGHV3-66 and IGHV4-38-2 germline genes, respectively. They possessed in vitro neutralizing ability, and in vivo protective efficacy against lethal infection with H3N2 or H7N9 virus. Escape mutations revealed that one of the protective antibodies recognized the α-helix A of HA2, and the other recognized the C-terminal portion of the fusion peptide and the β-sheet that precedes the α-helix A of HA2.
CONCLUSIONS: Of many human protective monoclonal antibodies against the HA stem, two human protective monoclonal antibodies were isolated in this study that predominantly recognize epitopes on the HA stem of group 2 and use unique IGHV3-66 and IGHV4-38-2 germline genes.
Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Group 2; HA stem; Human monoclonal antibody; Influenza A virus

Mesh:

Substances:

Year:  2017        PMID: 29248585      PMCID: PMC7066860          DOI: 10.1016/j.jinf.2017.12.004

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  41 in total

Review 1.  Evolution and ecology of influenza A viruses.

Authors:  R G Webster; W J Bean; O T Gorman; T M Chambers; Y Kawaoka
Journal:  Microbiol Rev       Date:  1992-03

2.  Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003.

Authors:  Jun Okada; Nobuko Ohshima; Ritsuko Kubota-Koketsu; Sayuri Ota; Wakana Takase; Masachika Azuma; Yoshitaka Iba; Naoko Nakagawa; Tetsushi Yoshikawa; Youichi Nakajima; Toyokazu Ishikawa; Yoshizo Asano; Yoshinobu Okuno; Yoshikazu Kurosawa
Journal:  Virology       Date:  2009-12-06       Impact factor: 3.616

3.  A highly conserved neutralizing epitope on group 2 influenza A viruses.

Authors:  Damian C Ekiert; Robert H E Friesen; Gira Bhabha; Ted Kwaks; Mandy Jongeneelen; Wenli Yu; Carla Ophorst; Freek Cox; Hans J W M Korse; Boerries Brandenburg; Ronald Vogels; Just P J Brakenhoff; Ronald Kompier; Martin H Koldijk; Lisette A H M Cornelissen; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Ian A Wilson; Jaap Goudsmit
Journal:  Science       Date:  2011-07-07       Impact factor: 47.728

4.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

5.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

6.  Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.

Authors:  M Gordon Joyce; Adam K Wheatley; Paul V Thomas; Gwo-Yu Chuang; Cinque Soto; Robert T Bailer; Aliaksandr Druz; Ivelin S Georgiev; Rebecca A Gillespie; Masaru Kanekiyo; Wing-Pui Kong; Kwanyee Leung; Sandeep N Narpala; Madhu S Prabhakaran; Eun Sung Yang; Baoshan Zhang; Yi Zhang; Mangaiarkarasi Asokan; Jeffrey C Boyington; Tatsiana Bylund; Sam Darko; Christopher R Lees; Amy Ransier; Chen-Hsiang Shen; Lingshu Wang; James R Whittle; Xueling Wu; Hadi M Yassine; Celia Santos; Yumiko Matsuoka; Yaroslav Tsybovsky; Ulrich Baxa; James C Mullikin; Kanta Subbarao; Daniel C Douek; Barney S Graham; Richard A Koup; Julie E Ledgerwood; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola; Adrian B McDermott
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

7.  H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Authors:  Irina Margine; Rong Hai; Randy A Albrecht; Gerlinde Obermoser; A Carson Harrod; Jacques Banchereau; Karolina Palucka; Adolfo García-Sastre; Peter Palese; John J Treanor; Florian Krammer
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

8.  Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.

Authors:  Ali H Ellebedy; Florian Krammer; Gui-Mei Li; Matthew S Miller; Christopher Chiu; Jens Wrammert; Cathy Y Chang; Carl W Davis; Megan McCausland; Rivka Elbein; Srilatha Edupuganti; Paul Spearman; Sarah F Andrews; Patrick C Wilson; Adolfo García-Sastre; Mark J Mulligan; Aneesh K Mehta; Peter Palese; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

9.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.

Authors:  Jens Wrammert; Dimitrios Koutsonanos; Gui-Mei Li; Srilatha Edupuganti; Jianhua Sui; Michael Morrissey; Megan McCausland; Ioanna Skountzou; Mady Hornig; W Ian Lipkin; Aneesh Mehta; Behzad Razavi; Carlos Del Rio; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Zahida Ali; Kaval Kaur; Sarah Andrews; Rama Rao Amara; Youliang Wang; Suman Ranjan Das; Christopher David O'Donnell; Jon W Yewdell; Kanta Subbarao; Wayne A Marasco; Mark J Mulligan; Richard Compans; Rafi Ahmed; Patrick C Wilson
Journal:  J Exp Med       Date:  2011-01-10       Impact factor: 14.307

10.  A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus.

Authors:  Ying Wu; MyungSam Cho; David Shore; Manki Song; JungAh Choi; Tao Jiang; Yong-Qiang Deng; Melissa Bourgeois; Lynn Almli; Hua Yang; Li-Mei Chen; Yi Shi; Jianxu Qi; An Li; Kye Sook Yi; MinSeok Chang; Jin Soo Bae; HyunJoo Lee; JiYoung Shin; James Stevens; SeoungSuh Hong; Cheng-Feng Qin; George F Gao; Shin Jae Chang; Ruben O Donis
Journal:  Nat Commun       Date:  2015-07-21       Impact factor: 14.919

View more
  2 in total

1.  Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.

Authors:  Mutsumi Ito; Seiya Yamayoshi; Kazushi Murakami; Kenji Saito; Atsuo Motojima; Kazunari Nakaishi; Yoshihiro Kawaoka
Journal:  Viruses       Date:  2019-02-11       Impact factor: 5.048

2.  Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018.

Authors:  Moe Okuda; Seiya Yamayoshi; Ryuta Uraki; Mutsumi Ito; Taiki Hamabata; Yoshihiro Kawaoka
Journal:  Viruses       Date:  2019-04-02       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.